GlassScriptPhysician profile
Henry Martinez
NPI 1801398235
$3,619.24
in general payments reported to CMS, 2019-2025
24 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.92 · 2023: $423 · 2024: $1,472 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.53 | 2023-2025 | |
| Teleflex LLC | $340.05 | 2024-2025 | Urolift, Barrigel |
| Sumitomo Pharma America, INC. | $324.97 | 2024-2025 | Gemtesa, Orgovyx |
| Procept Biorobotics Corporation | $249.04 | 2024-2025 | Aquabeam System |
| Bayer Healthcare Pharmaceuticals INC. | $239.54 | 2023-2025 | |
| Janssen Biotech, INC. | $209.02 | 2023-2025 | Erleada |
| Astellas Pharma US INC | $192.99 | 2024-2025 | Xtandi |
| Urogen Pharma, INC. | $167.68 | 2023-2025 | Jelmyto |
| Olympus America INC. | $139.91 | 2025 | Itind System |
| Endo Pharmaceuticals INC. | $137.89 | 2023-2024 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $133.40 | 2024-2025 | Adstiladrin |
| Pfizer INC. | $127.55 | 2024-2025 | |
| Endo USA, INC. | $123.89 | 2024-2025 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $112.77 | 2023-2024 | Pylarify |
| Merck Sharp & Dohme LLC | $108.33 | 2024 | Lynparza, Keytruda, Welireg |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $98.01 | 2024-2025 | Provenge |
| Tela Bio, INC. | $30.81 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Immunitybio, INC. | $30.76 | 2025 | |
| Blue Earth Diagnostics | $27.70 | 2024 | |
| Accord Healthcare, INC. | $21.97 | 2025 | |
| Smith+Nephew, INC. | $21.57 | 2022 | |
| Horizon Therapeutics Plc | $19.35 | 2022 | |
| Boston Scientific Corporation | $17.13 | 2024 | Ams 800 Artificial Urinary Sphincter |
| Halozyme INC | $13.38 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.